MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
4.450
-0.080
-1.77%
After Hours: 4.537 +0.087 +1.96% 19:55 03/26 EDT
OPEN
4.460
PREV CLOSE
4.530
HIGH
4.580
LOW
4.415
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
2.705
MARKET CAP
869.88M
P/E (TTM)
-25.4577
1D
5D
1M
3M
1Y
5Y
1D
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives
Simply Wall St · 3d ago
Arbutus Boosted by $2.25 Billion LNP Settlement and Hepatitis B Trial Progress
TipRanks · 3d ago
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate
Benzinga · 3d ago
Arbutus Biopharma advances imdusiran and AB-101 for chronic hepatitis B treatment
Reuters · 3d ago
*Arbutus Biopharma 2025 Rev $14.1M >ABUS
Dow Jones · 3d ago
ARBUTUS REPORTS FOURTH QUARTER AND YEAR END 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 3d ago
Weekly Report: what happened at ABUS last week (0316-0320)?
Weekly Report · 3d ago
Arbutus: Q4 Earnings Snapshot
Barchart · 3d ago
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.